Cancer-associated fibroblast

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors

Retrieved on: 
Friday, May 12, 2023
TNBC, Triple-negative breast cancer, Euronext Growth, TAA, Neoplasm, Gene editing, UCAR, Cancer, Cancer-associated fibroblast, Breast, FAP, Heterotrimeric G protein, CAF, Malignancy, Mesothelin, CAR, Patient, Extracellular matrix, TME, ISCB Senior Scientist Award, Mesothelioma, Cytokine, Tumor microenvironment, Vaccine, Medical imaging, Cellectis

Adoptive cell therapy based on chimeric antigen receptor-engineered T (CAR-T) cells has proven to be lifesaving for many cancer patients.

Key Points: 
  • Adoptive cell therapy based on chimeric antigen receptor-engineered T (CAR-T) cells has proven to be lifesaving for many cancer patients.
  • However, its therapeutic efficacy has so far been restricted to only a few malignancies, with solid tumors proving to be especially recalcitrant to efficient therapy.
  • Poor intra-tumor infiltration by T cells and T cell dysfunction due to a desmoplastic, immunosuppressive microenvironment are key barriers for CAR T-cell success against solid tumors.
  • CAF depletion in stroma rich solid tumors can thus provide an opportunity to convert immune evasive tumors susceptible to tumor-antigen CAR T-cell cytotoxicity.

Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer

Retrieved on: 
Wednesday, November 30, 2022
Research, General Health, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Growth, Colorectal cancer, Recurrence, TME, Science, OTC Markets Group, CAFS, Cancer-associated fibroblast, Lung, Journal, Kidney, Cell, PDAC, Immunosuppression, Mutation, MB, Pancreatic cancer, University, Cancer, Brain, Extracellular matrix, Patient, Enzyme, Trypsinogen, Tumor microenvironment, Pancreas, Liver, Prostate, Skin, Nature Communications, Accounting, Security (finance), Neoplasm, Prognosis, Metastasis, PRP, Fibroblast, Research, Bachelor of Medicine, Bachelor of Surgery, PPCB, Entrepreneurship, CAF, B cell, Chymotrypsinogen, Survival rate, Escape Room, FDA, Breast, Pharmaceutical industry, Medical imaging

Propanc Biopharma, Inc. (OTC Pink: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Chief Scientific Officer and Co-Founder, Dr. Julian Kenyon MD, MB, ChB, has recently come to the conclusion that PRP could become an effective chemosensitizer agent against pancreatic cancer.

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (Propanc or the Company), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Chief Scientific Officer and Co-Founder, Dr. Julian Kenyon MD, MB, ChB, has recently come to the conclusion that PRP could become an effective chemosensitizer agent against pancreatic cancer.
  • Pancreatic adenocarcinoma (PDAC) accounts for 80% of pancreatic cancers and has a 5-year survival rate of less than 8%.
  • This could have tremendous implications for PRP as a chemosensitizer agent with standard therapies to generate better clinical outcomes for PDAC patients.
  • Propanc Biopharma, Inc. (the Company) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers.

Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors

Retrieved on: 
Tuesday, May 31, 2022
Other Health, Research, Professional Services, Pharmaceutical, Oncology, Venture Capital, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Breast, Cell biology, Oncomatryx, Immunology, Immunotherapy, Tumor microenvironment, Bispecific monoclonal antibody, Patient, AEMPS, ADC, Control, University of Stuttgart, Institute, FDA, Fibroblast, IND, University, Hospital, Safety, Neoplasm, Drug resistance, Lung, Protein, Cancer-associated fibroblast, Immunosuppression, Pharmaceutical industry, Medical imaging

OMTX705 has already shown unbeatable safety in non-human primates and tumor regression in murine models of pancreatic, breast, lung and gastric cancer.

Key Points: 
  • OMTX705 has already shown unbeatable safety in non-human primates and tumor regression in murine models of pancreatic, breast, lung and gastric cancer.
  • Oncomatryx will run a multicenter, dose escalation trial in patients suffering metastatic solid tumors.
  • Oncomatryx, a global biopharmaceutical company, is pioneering the development of precision ADCs and bispecific antibodies against novel targets in the tumor microenvironment.
  • Oncomatryx is investing 50 million euros in 2022-2024, to develop OMTX705 and other novel tumor microenvironment-targeted ADCs and Bispecific antibodies.

Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration

Retrieved on: 
Monday, May 2, 2022
TEAD, COVID-19, Private Securities Litigation Reform Act, Twitter, GLOBE, Teaching hospital, Cancer-associated fibroblast, Physician, Tumor microenvironment, Patient, Trial of the century, Bristol Myers Squibb, Partnership, Vall, RAS, Neoplasm, Cancer, Knowledge, Precision medicine, LinkedIn, SEC, Research, Medical imaging, Pharmaceutical industry, Hippopotamus

The resulting research from this partnership will inform the further development of novel cancer therapies, including the ongoing programs in the Hippo and RAS pathways being developed by Ikena.

Key Points: 
  • The resulting research from this partnership will inform the further development of novel cancer therapies, including the ongoing programs in the Hippo and RAS pathways being developed by Ikena.
  • This partnership with the Vall dHebron Institute of Oncology reflects our commitment to leveraging multi-omic patient data and innovative translational models to inform the identification and development of therapies for specific cancer patient populations, said Jeffrey Ecsedy, Ph.D., Chief Development Officer at Ikena.
  • Specifically, this partnership will provide Ikena access to world class oncology researchers, novel tumor models and patient diagnostic, biomarker, and response data beyond what is available in the public domain.
  • Established in 2006, the Vall dHebron Institute of Oncology (VHIO) is a leading comprehensive cancer research center of excellence where its scientists and research physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer.

iBio Announces Collaboration with UT Southwestern to Investigate IBIO-100 in Solid Tumors

Retrieved on: 
Monday, November 15, 2021
DVM, Compliance, University, Maintenance, Cancer, Hydroponics, Breast, CDMO, Infection, Translational research, Immune system, Prognosis, CAF, Growth, BMC, Immunotherapy, Research, Tumor microenvironment, B cell, Cancer-associated fibroblast, Sale, Escape Room, Academic health science centre, Idiopathic pulmonary fibrosis, Protein, Vaccine, UT, Company, GLOBE, Fibroblast, SEC, NYSE American, NYSE, CAFS, Fibrosis, Time, Lung, Marketing, Pharmaceutical industry

IBIO-100 has shown strong therapeutic potential in preclinical models of two major fibrotic diseases, systemic scleroderma and idiopathic pulmonary fibrosis, and we look forward to exploring these same potentially transformative benefits in the treatment of solid tumors.

Key Points: 
  • IBIO-100 has shown strong therapeutic potential in preclinical models of two major fibrotic diseases, systemic scleroderma and idiopathic pulmonary fibrosis, and we look forward to exploring these same potentially transformative benefits in the treatment of solid tumors.
  • Through many years of research, we have come to understand that an overabundant fibrotic tumor microenvironment is associated with poor cancer treatment outcomes, commented Martin Brenner, DVM.
  • We look forward to exploring this potential with our partners at UT Southwestern.
  • The Companys wholly-owned subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with Glycaneering Development Services for advanced recombinant protein design.